232 related articles for article (PubMed ID: 21432905)
1. What is the impact of education on Huntington's disease?
López-Sendón JL; Royuela A; Trigo P; Orth M; Lange H; Reilmann R; Keylock J; Rickards H; Piacentini S; Squitieri F; Landwehrmeyer B; Witjes-Ane MN; Jurgens CK; Roos RA; Abraira V; de Yébenes JG;
Mov Disord; 2011 Jul; 26(8):1489-95. PubMed ID: 21432905
[TBL] [Abstract][Full Text] [Related]
2. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
[TBL] [Abstract][Full Text] [Related]
3. The relationship between CAG repeat length and clinical progression in Huntington's disease.
Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic characteristics in patients with Huntington's disease from China.
Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
[TBL] [Abstract][Full Text] [Related]
5. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.
Wexler NS; Lorimer J; Porter J; Gomez F; Moskowitz C; Shackell E; Marder K; Penchaszadeh G; Roberts SA; Gayán J; Brocklebank D; Cherny SS; Cardon LR; Gray J; Dlouhy SR; Wiktorski S; Hodes ME; Conneally PM; Penney JB; Gusella J; Cha JH; Irizarry M; Rosas D; Hersch S; Hollingsworth Z; MacDonald M; Young AB; Andresen JM; Housman DE; De Young MM; Bonilla E; Stillings T; Negrette A; Snodgrass SR; Martinez-Jaurrieta MD; Ramos-Arroyo MA; Bickham J; Ramos JS; Marshall F; Shoulson I; Rey GJ; Feigin A; Arnheim N; Acevedo-Cruz A; Acosta L; Alvir J; Fischbeck K; Thompson LM; Young A; Dure L; O'Brien CJ; Paulsen J; Brickman A; Krch D; Peery S; Hogarth P; Higgins DS; Landwehrmeyer B;
Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3498-503. PubMed ID: 14993615
[TBL] [Abstract][Full Text] [Related]
6. Unified Huntington's disease rating scale: clinical practice and a critical approach.
Klempír J; Klempírova O; Spacková N; Zidovská J; Roth J
Funct Neurol; 2006; 21(4):217-21. PubMed ID: 17367582
[TBL] [Abstract][Full Text] [Related]
7. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia.
Markianos M; Panas M; Kalfakis N; Vassilopoulos D
Ann Neurol; 2005 Apr; 57(4):520-5. PubMed ID: 15786456
[TBL] [Abstract][Full Text] [Related]
8. Exploring the correlates of intermediate CAG repeats in Huntington disease.
Ha AD; Jankovic J
Postgrad Med; 2011 Sep; 123(5):116-21. PubMed ID: 21904093
[TBL] [Abstract][Full Text] [Related]
9. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.
Margolis RL; O'Hearn E; Rosenblatt A; Willour V; Holmes SE; Franz ML; Callahan C; Hwang HS; Troncoso JC; Ross CA
Ann Neurol; 2001 Sep; 50(3):373-80. PubMed ID: 11558794
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in Huntington's disease: Which factors matter most?
Ho AK; Gilbert AS; Mason SL; Goodman AO; Barker RA
Mov Disord; 2009 Mar; 24(4):574-8. PubMed ID: 19097181
[TBL] [Abstract][Full Text] [Related]
11. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients.
Ribaï P; Nguyen K; Hahn-Barma V; Gourfinkel-An I; Vidailhet M; Legout A; Dodé C; Brice A; Dürr A
Arch Neurol; 2007 Jun; 64(6):813-9. PubMed ID: 17562929
[TBL] [Abstract][Full Text] [Related]
12. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
[TBL] [Abstract][Full Text] [Related]
13. [Huntington disease: clinical and genetic study in a Spanish population].
Solís Pérez MP; Palau Martínez F; Burguera Hernández JA; Salazar Cifré A
Neurologia; 1995 Nov; 10(9):362-6. PubMed ID: 8554791
[TBL] [Abstract][Full Text] [Related]
14. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J
Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775
[TBL] [Abstract][Full Text] [Related]
15. Effect of CAG repeat length on psychiatric disorders in Huntington's disease.
Vassos E; Panas M; Kladi A; Vassilopoulos D
J Psychiatr Res; 2008 Jun; 42(7):544-9. PubMed ID: 17610899
[TBL] [Abstract][Full Text] [Related]
16. Factors contributing to institutionalization in patients with Huntington's disease.
Rosenblatt A; Kumar BV; Margolis RL; Welsh CS; Ross CA
Mov Disord; 2011 Aug; 26(9):1711-6. PubMed ID: 21538527
[TBL] [Abstract][Full Text] [Related]
17. CAG mutation effect on rate of progression in Huntington's disease.
Squitieri F; Cannella M; Simonelli M
Neurol Sci; 2002 Sep; 23 Suppl 2():S107-8. PubMed ID: 12548366
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic characteristics of Mexican Huntington's disease patients.
Alonso ME; Ochoa A; Boll MC; Sosa AL; Yescas P; López M; Macias R; Familiar I; Rasmussen A
Mov Disord; 2009 Oct; 24(13):2012-5. PubMed ID: 19672992
[TBL] [Abstract][Full Text] [Related]
19. MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters.
Vymazal J; Klempír J; Jech R; Zidovská J; Syka M; Růzicka E; Roth J
J Neurol Sci; 2007 Dec; 263(1-2):20-5. PubMed ID: 17585943
[TBL] [Abstract][Full Text] [Related]
20. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
de Tommaso M; Specchio N; Sciruicchio V; Difruscolo O; Specchio LM
Mov Disord; 2004 Dec; 19(12):1516-8. PubMed ID: 15390067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
